

Special Issue

Hepatocellular Carcinoma: Advances and Challenges in Research and Treatment

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Although the etiology of viral-hepatitis-related HCC has decreased due to the deployment of aggressive medication and/or vaccines, the etiologies of alcoholic- or nonalcoholic-fatty-liver-disease-related HCC are increasing. The importance of the clinical prevention and management of HCC still cannot be overstated. The new version of the BCLC guidelines recommends corresponding treatment strategies and clinical-outcome estimations for different stages of the disease. However, there still remain other unrecommended treatment modalities which may be beneficial, especially for the advanced HCC patients. This Special Issue will reflect the recent advances in the research and treatment of HCC, including surgical resection, liver transplant, image-guided tumor ablation, conventional/drug-eluting chemoembolization, Y-90 radioembolization, new regimens of hepatic arterial infusion chemotherapy, proton beam radiotherapy, target/immunotherapy, and/or combination therapy.

Guest Editor

Dr. Huei-Lung Liang

Department of Radiology, Kaohsiung Veterans General Hospital, 386
Dazhong 1st Rd, Kaohsiung 813, Taiwan

Deadline for manuscript submissions

closed (30 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/141128

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)